| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Purine nucleoside metabolism pathways, DNA synthesis. As a purine nucleoside analog, 4-Thio-2'-deoxyuridine is incorporated into DNA, disrupting nucleic acid synthesis. The compound targets rapidly dividing cells, particularly lymphoid malignancies. The thio group at position 4 confers photoactivity, allowing selective photoactivation.
|
|---|---|
| ln Vitro |
4-Thio-2'-deoxyuridine demonstrates activity as a purine nucleoside analog in cellular assays. It has broad-spectrum anticancer effects. The compound inhibits DNA synthesis and induces apoptosis in cancer cells. Its photoactive properties enable light-induced cross-linking to DNA. Detailed IC50 values have not been disclosed.
|
| ln Vivo |
In vivo activity of 4-Thio-2'-deoxyuridine has not been extensively characterized in published literature. As a purine nucleoside analog, it would be expected to have antitumor activity in animal models. Its photoactive properties could enable photodynamic therapy approaches. In vivo studies would be needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for purine nucleoside analogs typically involve measuring inhibition of DNA synthesis using radiolabeled thymidine incorporation. For photoactive analogs, cells are treated with the compound and exposed to UV light at 340 nm to induce cross-linking. Cell viability is assessed by MTT or CellTiter-Glo assays. Apoptosis is evaluated by caspase activation or Annexin V staining.
|
| Cell Assay |
Cells (e.g., lymphoid malignancy cell lines or other cancer cell lines) are cultured and treated with 4-Thio-2'-deoxyuridine at concentrations typically ranging from 0.1–100 μM for 24–72 hours. For photoactivation studies, cells are exposed to 340 nm light after compound treatment. DNA synthesis inhibition is measured by BrdU incorporation. Cell viability and apoptosis are assessed by standard assays.
|
| Animal Protocol |
In vivo animal studies for 4-Thio-2'-deoxyuridine have not been reported in publicly available literature. The compound is primarily used as a research tool for nucleoside analog and photoactivation studies. Future studies in xenograft models or photodynamic therapy models would be needed to evaluate in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 4-Thio-2'-deoxyuridine have not been published. The compound has a molecular weight of 244.27 and formula C9H12N2O4S. The thio group may affect metabolic stability and tissue distribution. In vivo PK parameters such as half-life, bioavailability, and tissue distribution have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 4-Thio-2'-deoxyuridine have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling nucleoside analogs and photoactive compounds should be observed.
|
| References | |
| Additional Infomation |
4-Thio-2'-deoxyuridine (CAS: 5580-20-1, molecular formula C9H12N2O4S, molecular weight 244.27) is a purine nucleoside analog and photoactive compound. It absorbs light at ~340 nm and can be selectively photoactivated. It is not in clinical trials and has no regulatory approval. The compound is supplied as a research-grade nucleoside analog for laboratory use only.
|
| Molecular Formula |
C9H12N2O4S
|
|---|---|
| Molecular Weight |
244.27
|
| Exact Mass |
244.052
|
| CAS # |
5580-20-1
|
| PubChem CID |
3034650
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.59g/cm3
|
| Melting Point |
169 °C
|
| Index of Refraction |
1.697
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
346
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@@H]([C@H](O[C@H]1N2C=CC(=S)NC2=O)CO)O
|
| InChi Key |
PHNDUXLWAVSUAL-SHYZEUOFSA-N
|
| InChi Code |
InChI=1S/C9H12N2O4S/c12-4-6-5(13)3-8(15-6)11-2-1-7(16)10-9(11)14/h1-2,5-6,8,12-13H,3-4H2,(H,10,14,16)/t5-,6+,8+/m0/s1
|
| Chemical Name |
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidenepyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0938 mL | 20.4692 mL | 40.9383 mL | |
| 5 mM | 0.8188 mL | 4.0938 mL | 8.1877 mL | |
| 10 mM | 0.4094 mL | 2.0469 mL | 4.0938 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
